43. (As filed) The method of claim 42 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

44. (As filed) The method of claim 42 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

45. (As filed) The method of claim 41 wherein the Apo-2 ligand polypeptide is selected from the group:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide comprising a fragment or variant of (a); and

(c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

46. (As filed) The method of claim 41 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

47. (As filed) A method of treating a mammal having glioma or glioblastoma cancer, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's glioma or glioblastoma cells.

48. (As filed) The method of claim 47 wherein radiation therapy or chemotherapy is further administered to the mammal.

49. (As filed) The method of claim 48 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

50. (As filed) The method of claim 48 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil,

Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

51. (As filed) The method of claim 47 wherein the Apo-2 ligand polypeptide is selected from the group:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide comprising a fragment or variant of (a); and

(c) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

52. (As filed) The method of claim 47 wherein the Apo-2 ligand polypeptide is linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

Please add the following claims:

--- 59. A method of treating a mammal having neuroblastoma cancer, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's neuroblastoma cancer cells, wherein said Apo-2 ligand polypeptide is selected from the group consisting of:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(c) a polypeptide consisting of amino acid residues 1-281 of Figure 1A (SEQ ID NO:1);

(d) a polypeptide which is a fragment of (a), (b) or (c).

60. The method of claim 59 wherein radiation therapy or chemotherapy is also administered to the mammal.

61. The method of claim 60 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

62. The method of claim 60 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered sequentially.

63. The method of claim 60 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

64. The method of claim 59 wherein said Apo-2 ligand polypeptide consists of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

65. The method of claim 59 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

B2 cont.

66. The method of claim 64 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

67. The method of claim 59 wherein said Apo-2 ligand polypeptide is unglycosylated.

68. The method of claim 67 wherein said Apo-2 ligand polypeptide is produced in *E. coli*.

B3

69. A method of treating a mammal having glioma or glioblastoma cancer, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's glioma or glioblastoma cells, wherein said Apo-2 ligand polypeptide is selected from the group consisting of:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(c) a polypeptide consisting of amino acid residues 1-281 of Figure 1A (SEQ ID NO:1);

(d) a polypeptide which is a fragment of (a), (b) or (c).

70. The method of claim 69 wherein radiation therapy or chemotherapy is also administered to the mammal.

71. The method of claim 70 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

72. The method of claim 70 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered sequentially.

73. The method of claim 70 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

74. The method of claim 69 wherein said Apo-2 ligand polypeptide consists of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

75. The method of claim 69 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

76. The method of claim 74 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

77. The method of claim 69 wherein said Apo-2 ligand polypeptide is unglycosylated.

B2 cont.

78. The method of claim 77 wherein said Apo-2 ligand polypeptide is produced in *E. coli*. ---